Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)
NCT01597258
·
clinicaltrials.gov ↗
COMPLETED
Status
2029
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
Crizotinib (Xalkori)
Sponsor
Pfizer